W.P. Burkard - Concepedia

Author

W.P. Burkard

Roche (Switzerland)

Also Known As

W BURKARD, W Burkard, W P Burkard, W. BURKARD, W. Burkard, W. P. BURKARD, W. P. Burkard, W.P. Burkard, Walter Burkard

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Roche (Switzerland)

About

W.P. Burkard is an author at Roche (Switzerland) specializing in medicine, pharmacology, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	31	2K
2	Social Sciences	13	13	1.1K
3	Biochemistry	11	11	397
4	Health Sciences	5	5	252
5	Natural Sciences	5	5	167

W.P. Burkard

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Increase of Cerebral Catecholamines caused by 3,4-Dihydroxyphenylalanine after Inhibition of Peripheral Decarboxylase G. Bartholini, W.P. Burkard, A. Pletscher, Nature NeurophysiologyNeuroanatomyMedicineNeuropharmacologyPeripheral Decarboxylase	1967	243
Benzodiazepine Antagonist Ro 15–1788: Binding Characteristics and Interaction with Drug‐Induced Changes in Dopamine Turnover and Cerebellar cGMP Levels H. Möhler, W.P. Burkard, H. H. Keller, Journal of Neurochemistry PsychopharmacologyPharmacotherapySocial SciencesMolecular PharmacologyMedicinal Chemistry	1982	223
Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. M. Da Prada, R. Kettler, H. H. Keller, Journal of Pharmacology and Experimental Therapeutics	1989	199
Blockade of central 5-hydroxytryptamine receptors by methiothepin M. A. Monachon, W.P. Burkard, M Jalfre, Naunyn-Schmiedeberg s Archives of Pharmacology Central 5-Hydroxytryptamine ReceptorsMedicineNeuropeptide ReceptorNeuropharmacologyPharmacotherapy	1972	143
CHLORINATED ARYLALKYLAMINES AFFECTING THE CEREBRAL METABOLISM OF 5-HYDROXYTRYPTAMINE A. Pletscher, G. Bartholini, H. Bruderer, Journal of Pharmacology and Experimental Therapeutics	1964	128
Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis L. Pieri, H. H. Keller, W.P. Burkard, Nature NeuropsychologyCerebral Monoamine SystemsPsychoactive DrugNeurophysiologyMedicine	1978	124
Neurally mediated control of enzymes involved in the synthesis of norepinephrine; are they regulated as an operational unit? H. Thoenen, R. Kettlee, W.P. Burkard, Naunyn-Schmiedeberg s Archives of Pharmacology NeurophysiologyMedicinePhysiologyNeuroendocrine MechanismNeurotransmission	1971	95
Inhibition of decarboxylase of aromatic amino acids by 2,3,4-trihydroxybenzylhydrazine and its seryl derivative W.P. Burkard, K.F. Gey, A. Pletscher Archives of Biochemistry and Biophysics Bioorganic ChemistryAldehyde DehydrogenaseBiochemistryNatural SciencesMedicine	1964	91
Ro 16-6028: A Novel Anxiolytic Acting as a Partial Agonist at the Benzodiazepine Receptor L. Pieri, E. Bonetti, R. Schaffner, Pharmacopsychiatry BiochemistryMedicinePsychotropic MedicationMechanism Of ActionRo 16-6028	1988	89
<i>In vivo</i> changes of guanosine 3′,5′ ‐cyclic phosphate in rat cerebellum by dopaminergic mechanisms W.P. Burkard, L. Pieri, W. Haefely Journal of Neurochemistry Molecular Physiology‐Cyclic PhosphateNeurophysiologyPhysiologyDopaminergic Mechanisms	1976	76

Page 1